 Home > Active Ingredient News > Blood System > J Clin Oncol: Efficacy and safety of sorafenib combined with standard chemotherapy in children with FLT3/ITD+ acute myeloid leukemia

J Clin Oncol: Efficacy and safety of sorafenib combined with standard chemotherapy in children with FLT3/ITD+ acute myeloid leukemia

 Last Update: 2022-05-15
 Source: Internet
 Author: User

Tags

used 2 iron

dexmethylphenidate 10 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

FLT3 is a receptor tyrosine kinase that is mutated in approximately 10%-15% of new-onset acute myeloid leukemia (AML) pediatric

leukemia childhood stem cells

The COG AAML1031 study evaluated the efficacy and feasibility of adding the multikinase tyrosine kinase inhibitor sorafenib to standard chemotherapy regimens and maintaining sorafenib monotherapy in this patient population

The test patients were divided into three cohorts

The measured plasma concentrations are sufficient to inhibit phosphorylated FLT3

HAR FLT3/ITD+ patients not treated with sorafenib had approximately twice the risk of certain endpoint events than patients receiving sorafenib HAR FLT3/ITD+ patients not treated with sorafenib had certain endpoints The risk of events was approximately twice as high as in patients treated with sorafenib

In conclusion, this study shows that the addition of sorafenib to the conventional chemotherapy regimen in children with HAR FLT3/ITD positive acute myeloid leukemia is feasible and safe, and is expected to improve the clinical prognosis of the children

It is feasible and safe to add sorafenib to routine chemotherapy in children with HAR FLT3/ITD positive acute myeloid leukemia, and it is expected to improve the clinical prognosis of children

Original source:

Jessica A.

Jessica A.
Pollard, et al.
Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031.
Journal of Clinical Oncology.
March 29, 2022.
https:/ /ascopubs.
org/doi/full/10.
1200/JCO.
21.
01612

leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Food Additive Iron fumarate for Nutritional Iron Supplements

CAS No.: 141-01-5

Pharmacy Grade

$24-26/G FOB

Aminobenzoic Acid CAS 56-91-7

CAS No.: 56-91-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.